Skip to main content

Month: September 2021

Dimensional Fund Advisors Ltd. : Form 8.3 – MEGGITT PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate...

Continue reading

Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for toripalimab in combination with gemcitabine and cisplatin for first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and toripalimab monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA recently granted Breakthrough Therapy Designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for 1st line treatment...

Continue reading

Vera Bradley Announces Second Quarter Fiscal Year 2022 Results

Consolidated net revenues totaled $147.0 million for the second quarter, an increase of 11.6% over the prior year Company posted second quarter net income of $9.1 million, or $0.26 per diluted share; excluding certain items, non-GAAP net income totaled $9.5 million, or $0.28 per diluted share Balance sheet remains strong, with cash, cash equivalents, and investments over $76 million, and no debt Management updates annual guidance for fiscal year ending January 29, 2022 FORT WAYNE, Ind., Sept. 01, 2021 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) today announced its financial results for the second quarter ended July 31, 2021. In this release, Vera Bradley, Inc. or “the Company” refers to the entire enterprise and includes both the Vera Bradley and Pura Vida brands. “Vera Bradley” on a stand-alone basis refers only to the...

Continue reading

Etrion has applied for delisting of its shares from TSX and intends to apply for delisting of its shares from Nasdaq Stockholm

GENEVA, Sept. 01, 2021 (GLOBE NEWSWIRE) — Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX) announces that further to the recent sale of substantially all of the Company’s assets and the return of capital to shareholders that was completed on August 24, 2021, and in order to minimize the costs and management time associated with the listing of the Corporation’s common shares (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”) and Nasdaq Stockholm (“Nasdaq”) pending a determination of whether the Company should pursue an alternative business or an orderly dissolution and winding-up of the Company, the Company has applied to voluntarily delist the Common Shares from the TSX. Such delisting will become effective after the close of trading on September 17, 2021. The Company also intends to apply to delist...

Continue reading

Bergman & Beving acquires 3 Screen

Press release Bergman & Beving acquires 3 Screen Workplace Safety, a division within Bergman & Beving, has today acquired all shares in (3) Screen Tryck AB. 3 Screen will become part of the business area Safety & Industrial Signage (SIS Group), together with the companies Systemtext and JO Safety. 3 Screen is a niche producer of workplace safety signage products. The acquisition brings unique production capabilities of patented products. The company has an annual turnover of approximately MSEK 7 with strong profitability and is based in Malmö with five employees. “With the acquisition of 3 Screen, we continue to invest in the niche market of workplace safety signage”, says Fredrik Valentin, Head of Division Workplace Safety. “We intend to further develop the company as an integrated part of SIS Group, gaining competitive...

Continue reading

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. Event: H.C. Wainwright 23rd Annual Global Investment ConferenceMonday, September 13 – Wednesday, September 15 A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am EDT, Monday, September 13. It can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About...

Continue reading

Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company’s Chief Medical Officer (“CMO”). Dr. Buck joins Caladrius from ICON plc (“ICON”), a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries. During her time at ICON, Dr. Buck served as its CMO, where she represented the company’s position on key scientific, ethical, and medical governance matters, provided guidance and oversight to the medical and scientific groups, and led the Drug Development Services group. Prior to that,...

Continue reading

Atos completes the acquisition of German cryptography specialist cryptovision and strengthens its cybersecurity product line

Paris, France and Munich, Germany – September 1, 2021 – Atos today announced that it has completed the acquisition of cv cryptovision GmbH, a leader in advanced cryptographic products and solutions for securing digital identities. In addition to bringing new technical capabilities and cybersecurity products to the Group’s portfolio, the acquisition will enable Atos to expand its business in the public sector and defense market in Europe, to strengthen its position in global government eID initiatives, and to grow its footprint in emerging IoT markets. cryptovision designs, develops and implements cryptography solutions, software and hardware products which are made in Germany and meet the most demanding regulations, certifications and security standards (accredited by the German Federal Office for Information Security and NATO; certified...

Continue reading

Laurentian Bank Financial Group reports third quarter 2021 results

The financial information reported herein is based on the condensed interim consolidated (unaudited) information for the three-month period ended July 31, 2021, and has been prepared in accordance with International Financial Reporting standards (IFRS), as issued by the International Accounting Standards Board (IASB). All amounts are denominated in Canadian dollars. The Laurentian Bank of Canada and its entities are collectively referred to as Laurentian Bank Financial Group (the “Group” or the “Bank”) and provide deposit, investment, loan, securities, trust and other products or services.Highlights of third quarter 2021 (compared with third quarter 2020)Reported net income of $62.1 million, compared with $36.2 million. Adjusted net income(1) of $59.0 million, compared with $47.1 million. Diluted earnings per share of $1.32, compared...

Continue reading

Entourage Health Announces New Ticker Symbol on U.S.-Based OTCQX Market as ‘ETRGF’ Effective September 1, 2021

TORONTO, Sept. 01, 2021 (GLOBE NEWSWIRE) — Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX: ETRGF), (formerly OTCQX: WDDMF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and brands, announced that effective at market open on September 1, 2021, the OTCQX market ticker symbol for the Company’s common shares will change from “WDDMF” to “ETRGF”. The OTCQX symbol change is consistent with the Company’s rebranding from WeedMD Inc. to Entourage Health Corp. announced earlier this year. The Company’s common shares continue to trade primarily on the TSX Venture Exchange (“TSXV”) under the symbol “ENTG” and Frankfurt Stock Exchange (“FSE”) under the symbol ”4WE”. About Entourage Health Corp. Entourage Health Corp. (formerly WeedMD Inc.) is the publicly traded...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.